As of Thursday close, Pfizer Inc.’s (NYSE:PFE) stock was up $1.02, moving up 2.08 percent to $50.09. The average number of shares traded per day over the past five days has been 25,108,119 shares. 5 times new highs have been achieved over the past 5 days, with a $1.58 gain in that time frame. In the last twenty days, the average volume was 23,992,385, while in the previous 50 days, it was 24,711,555.
Since last month, PFE stock retreated -5.28%. Shares of the company fell to $46.28 on 06/17/22, the lowest level in the past month. A 52-week high of $61.71 was reached on 01/03/22 after having rallying from a 52-week low of $38.82. Since the beginning of this year, PFE’s stock price has dropped by -15.17% or -$8.96, and marked a new high 1 time. However, the stock has declined by -18.83% since its 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Pfizer Inc. (PFE) last reported insider trading activity 17 days ago on Jun 07. DAMICO JENNIFER B., the SVP & Controller of the company, disposed of 4,218 shares for $53.96 on Jun 07. It resulted in a $227,603 divestment by the insider. DAMICO JENNIFER B. sold 4,000 shares at an average price of $50.50 on May 16. The insider now owns 15,064 shares following the transaction. On May 13, Executive Vice President SAHNI PAYAL sold 1,408 shares at $49.84 apiece. The transaction was valued at $70,175.
Right now, Pfizer Inc. (PFE) has a P/E ratio of about 11.29. The stock’s beta is 0.77. Besides these, the trailing price-to-sales (P/S) ratio of 3.10, the price-to-book (PB) ratio of 3.41, and the price-to-cash flow ratio of 12.48 may also be considered.
The latest dividend of $0.40 per share was paid out, remained unchanged from last year’s $0.40. On Friday December 10 2021, a $0.01 dividend increase was announced.
In the three months ended March 30, Pfizer Inc.’s quick ratio stood at 1.10, while its current ratio was 1.40, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending March 30 was 0.43, and the total debt-to-equity ratio was 0.44. On the profitability front, the trailing twelve-month gross margin is 60.40% percent. In the year ended March 30, operating margins totaled 30.30%. Based on annual data, PFE earned $50.47 billion in gross profit and brought in $81.29 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 18.90%. Return on equity (ROE) for the past 12 months was 32.70%.
In Pfizer Inc.’s quarter-end financial report for March 30, it reported total debt of $35.66 billion against cash and short-term investments of $21.43 billion. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. PFE’s revenue rose 43.17% to $23.64 billion during the quarter, while net income inched up to $25.66 billion. While analysts expected Pfizer Inc. to report $1.47 quarterly earnings, the actual figure was $1.67 per share, beating the consensus estimate by 13.60%. During the quarter, the company generated $10.59 billion in EBITDA. The liabilities of Pfizer Inc. were 101.16 billion at the end of its most recent quarter ended March 30, and its total debt was $36.44 billion. The value of shareholders’ equity is $5.61 billion.
This quick technical analysis looks at Pfizer Inc.’s (PFE) price momentum. With a historical volatility rate of 40.41%, the RSI 9-day stood at 51.45% on 23 June.
With respect to its five-day moving average, the current Pfizer Inc. price is up by +3.26% percent or $1.58. At present, PFE shares trade -6.22% below its 20-day simple moving average and -7.80% percent below its 100-day simple moving average. However, the stock is currently trading approximately -7.12% below its SMA50 and +7.14% above its SMA200.
Stochastic coefficient K was 33.94% and Stochastic coefficient D was 20.97%, while ATR was 1.54. Given the Stochastic reading of 46.01% for the 14-day period, the RSI (14) reading has been calculated as 48.98%. As of today, the MACD Oscillator reading stands at 0.69, while the 14-day reading stands at -1.00.
SVB Leerink launched its rating on Pfizer Inc. (NYSE: PFE) to a Mkt perform in a note to investors on May 23, 2022. Pfizer Inc. (PFE) has been rated Overweight by analysts. According to 0 brokerage firms, PFE is a sell, and 14 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Pfizer Inc. stock as buy, with 9 recommending it as overweight.
With a median target price of $55.00, the current consensus forecast for the stock is $49.00 – $75.00. Based on these forecasts, analysts predict Pfizer Inc. (PFE) will achieve an average price target of $57.61.